darbepoetin alfa

(redirected from Aranesp)
Also found in: Medical.
Translations

darbepoetin alfa

n darbepoetina alfa
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
including involvement in the marketing of Aranesp and acting as global government affairs director in the company's Washington DC office.
TRILO2GY Phase 3 Study: New study design includes once-daily and three-times-weekly dosing and an ESA control, as well as a larger sample size; this study will replace the former TRILO2GY study, Designed to generate data to inform switching from Epogen, Aranesp and Mircera, Expected to initiate in late 2018 or early 2019, with top-line results expected in early 2020.
In addition, the European patent for the second-generation erythropoietin medicine, Aranesp expired in August 2014.
The 50-50joint venture was launched in 1984 to fund the global development of Epogen (epoetin alfa) and, over time, was expanded to include Neupogen (filgrastim), Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa), Nplate (romiplostim) and brodalumab.
Over time, the scope of the collaboration was expanded to include NEUPOGEN (filgrastim), Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa), Nplate (romiplostim) and brodalumab.
The patent expiry of drugs such as Epogen and Aranesp, combined with the establishment of a proper regulatory framework for biosimilar approval within the US are expected to be the major factors influencing the growth of the market segment over the forecast period.
In addition, Amgen currently owns the patent Aranesp for Darbepoetin alfa; which is expected to expire by 2016, thus, calling for launch of Darbepoetin Alfa biosimilars.
Another pivotal trial for ESA use for anemia management was the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) (Goldsmith & Covic, 2010).
This is the result of three recent major randomized controlled trials--Correction of Hemoglobin and Outcomes In Renal insufficiency (CHOIR), Cardiovascular Risk reduction in Early Anemia Treatment with Epoetin beta (CREATE), and Trial to Reduce cardiovascular Events with Aranesp Therapy (TREAT)--which provide evidence that there may be more risk than benefit at higher Hb targets (Drueke et al., 2006; Pfeffer et al., 2009; Singh et al., 2006).
In 2005, Amgen stock was trading at $86.17, flying high on strong sales of its anemia drug Aranesp, which the company was aggressively marketing.
Aranesp (darbepoetin alfa) sales decreased 15 percent to $538 million in the fourth quarter of 2011 versus $633 million in the fourth quarter of 2010.